We recently compiled a list of the 15 Best Cheap Stocks to Buy for 2025. In this article, we are going to take a look at ...

This issue is preventing our website from loading properly. Please review the following troubleshooting tips or contact us at [email protected]. By submitting your email, you agree to the Privacy ...

THE COURT of Tax Appeals (CTA) has ordered the Bureau of Internal Revenue (BIR) to refund P14.59 million to the local branch of United States-based pharmaceutical company Merck Sharp & Dohme (MSD), ...

The American Chamber of Commerce in Vietnam (AmCham Vietnam) on Friday announced Dr. Dam Thi Hoang Lan, external affairs director at MSD Vietnam, as its new chair for the 2025 term. The new chair ...

Merck's stock had a mixed year in 2024, with prices ranging from a low of $94.48 in November to a high of $134.63 in June — a ...

Melanoma Among Adult Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study Adults with stage IB-IIIA (American Joint Committee on Cancer seventh edition) resectable NSCLC ...

The new marketing authorization was granted on December 27 to Merck (MRK) Sharp & Dohme Limited. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news.

Merck Sharp & Dohme LLC has patented new 5,6 saturated bicyclic heterocyles acting as NLRP3 inflammasome inhibitors potentially useful for the treatment of atherosclerosis, metabolic ...

Merck Sharp & Dohme is in dispute with Clonmel Healthcare and, separately, Teva Finland over SPC rights for different combination products before those national courts. First, having confirmed the ...

Merck Sharp & Dohme LLC has divulged NLRP3 inflammasome inhibitors reported to be useful for the treatment of atherosclerosis, nonalcoholic or metabolic dysfunction-associated steatohepatitis ...

Outside the United States and Canada, it is known as MSD/Merck Sharp and Dohme. It is one of the largest drug companies in the world and often is ranked in the top 5 for revenue. This large ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of data from the Phase 2 waveLINE-007 trial ...